Opinion|Videos|July 18, 2024
NCCN Guidelines Revisions and ASCO 2024 Research Outlook
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series
- How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
- What data, results, or insights are you looking forward to coming out of ASCO 2024?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
2
The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine
3
Photobiomodulation, Bio-Machines, and the Future of Dermatology
4
Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026
5
